Selection and optimization strategy for Rap1-targeting single-domain antibodies as platelet activation markers

TL;DR

This paper describes the development of specialized antibodies that can detect active Rap1 in platelets, offering new tools for studying platelet activation and its role in health and disease.

Contribution

The study introduces optimized single-domain antibodies (VHH-Fc) that specifically detect active Rap1 in platelets and a reliable ELISA assay for quantifying active Rap1.

Findings

Two optimized VHH-Fc clones (B89 and B14) effectively capture active Rap1 in platelets.

An ELISA setup using VHH-Fc B14 and a commercial antibody accurately quantifies endogenous active Rap1.

The developed tools can detect active Rap1 in platelet lysates and HeLa cells overexpressing active Rap1B.

Abstract

Rap1 is critical for platelet activation, functioning as a key node of the platelet activation pathways.

This study aimed to develop VHH-Fc (minibodies) against Rap1 for the purpose to quantify active Rap1 levels in platelets.

We have produced the first generation of VHHs against active Rap1 through a series of negative and positive screenings of a synthetic phage display library, utilizing both inactive and active Rap1B. We performed random mutagenesis, followed by yeast 2-hybrid screening to optimize variants.

Among 122 VHH clones, 2 with the highest redundancy were subcloned as VHH-Fc. Both selectively detected active Rap1B G12V in HeLa cells but failed to recognize the inactive Rap1B S17N isoform. They successfully captured Rap1 from platelet lysates incubated with GTPγS and from thrombin receptor activator peptide 6–stimulated platelets. Further optimization yielded 2 superbinder VHH clones: VHH-Fc B89 and VHH-Fc B14. VHH-Fc B89 exhibited a KD of 4.4 nM and showed enhanced capacity to capture active GTP-bound Rap1 compared with the original VHH-Fc. Additionally, it was able to detect overexpressed active Rap1B G12V in HeLa cells. An ELISA setup combining VHH-Fc B14 and a commercial monoclonal antibody targeting total Rap1 was highly effective in detecting both GTPγS-bound Rap1 and endogenous active Rap1 in platelets.

This study identifies, that accurately capture active Rap1 in platelets, thereby establishing them as promising tools for future research. We also developed a reliable ELISA test that can facilitate clinical studies to monitor platelet Rap1 activation in various medical contexts.

•Rap1 is a critical GTPase involved in platelet activation.•A synthetic phage display library was screened to identify VHH targeting active Rap1.•Several VHH-Fc were found to effectively capture active Rap1 in platelets.•A VHH-fc–based ELISA assay was developed than accurately quantify endogenous active Rap1 in platelets.

Rap1 is a critical GTPase involved in platelet activation.

A synthetic phage display library was screened to identify VHH targeting active Rap1.

Several VHH-Fc were found to effectively capture active Rap1 in platelets.

A VHH-fc–based ELISA assay was developed than accurately quantify endogenous active Rap1 in platelets.

Figures